Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(5); doi: 10.25236/AJMHS.2023.040516.

Research Progress on Pathological Mechanism and Treatment of Parkinson's Disease


Jing Meng1, Qiang Wang2

Corresponding Author:
Qiang Wang

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

2College of Acupuncture and Massage, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China


Parkinson's disease (PD) is a neurodegenerative disease caused by the degeneration and loss of dopaminergic neurons in the substantia nigra pars compacta. The hallmark pathological feature is the presence of Lewy bodies consisting of abnormal aggregation of α-synuclein. This paper summarizes and analyzes the latest relevant literature at home and abroad in recent years, and finds that the pathological mechanism of Parkinson's disease is complex and can interact with each other. At present, the drugs for the treatment of PD are single and have great side effects. Surgical treatment has a certain risk and high price, while acupuncture treatment has the characteristics of good effect, low cost and no side effects, and plays a huge role in the treatment of PD.


Parkinson's disease; Pathological mechanism; Drug treatment; Acupuncture treatment

Cite This Paper

Jing Meng, Qiang Wang. Research Progress on Pathological Mechanism and Treatment of Parkinson's Disease. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 5: 101-106. https://doi.org/10.25236/AJMHS.2023.040516.


[1] Burré Jacqueline et al.”Definition of a molecular pathway mediating α-synuclein neurotoxicity.” The Journal of neuroscience: the official journal of the Society for Neuroscience vol. 35, 13 (2015): 5221-32. 

[2] Ghosh Dhiman et al.”α-synuclein aggregation and its modulation.” International journal of biological macromolecules vol. 100 (2017): 37-54. 

[3] Creed Rose B, and Matthew S Goldberg.” New Developments in Genetic rat models of Parkinson's Disease.” Movement disorders: official journal of the Movement Disorder Society vol. 33, 5 (2018): 717-729. 

[4] Keeney Paula M et al.”Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled.”The Journal of neuroscience: the official journal of the Society for Neuroscience vol. 26, 19 (2006): 5256-64. 

[5] Terron Andrea et al.”An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.” Archives of toxicology vol. 92, 1 (2018): 41-82. 

[6] Cannon Jason R, and J Timothy Greenamyre.”Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.” Neurobiology of disease vol. 57 (2013): 38-46. 

[7] Meredith Gloria E, and David J Rademacher.”MPTP mouse models of Parkinson's disease: an update.”Journal of Parkinson's disease vol. 1, 1 (2011): 19-33. 

[8] Devi Latha et al.”Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.”The Journal of biological chemistry vol. 283, 14 (2008): 9089-100. 

[9] Puspita Lesly et al.”Oxidative stress and cellular pathologies in Parkinson's disease.”Molecular brain vol. 10, 1 53. 28 Nov. 2017.

[10] Cobley James Nathan et al.”13 reasons why the brain is susceptible to oxidative stress.”Redox biology vol. 15 (2018): 490-503. 

[11] Masato Anna et al.”Impaired dopamine metabolism in Parkinson's disease pathogenesis.” Molecular neurodegeneration vol. 14, 1 35. 20 Aug. 2019, 

[12] Cenini Giovanna et al.”Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View.” Oxidative medicine and cellular longevity vol. 2019 2105607. 9 May. 2019.

[13] Jayaram Saravanan, and Praveen Thaggikuppe Krishnamurthy.”Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators.”Neurochemistry international vol. 145 (2021): 105014. 

[14] Colonna Marco, and Oleg Butovsky.”Microglia Function in the Central Nervous System during Health and Neurodegeneration.”Annual review of immunology vol. 35 (2017): 441-468. 

[15] Antonangeli Fabrizio et al.”Senescent cells: Living or dying is a matter of NK cells.”Journal of leukocyte biology vol. 105, 6 (2019): 1275-1283. 

[16] Williams Gregory P et al.”CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.” Brain: a journal of neurology vol. 144, 7 (2021): 2047-2059. 

[17] Pacheco Rodrigo.”Cross-talk between T-cells and gut-microbiota in neurodegenerative disorders.”Neural regeneration research vol. 14, 12 (2019): 2091-2092. 

[18] Braak Heiko et al.”Staging of brain pathology related to sporadic Parkinson's disease.” Neurobiology of aging vol. 24, 2 (2003): 197-211. 

[19] Braak Heiko et al.”Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.”Neuroscience letters vol. 396, 1 (2006): 67-72. 

[20] Klingelhoefer Lisa, and Heinz Reichmann.”The Gut and Nonmotor Symptoms in Parkinson's Disease.”International review of neurobiology vol. 134 (2017): 787-809. 

[21] Sampson Timothy R et al.”Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.”Cell vol. 167, 6 (2016): 1469-1480. e12. 

[22] Ghosh Siddhartha S et al.”Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development.”Journal of the Endocrine Society vol. 4, 2 bvz039. 20 Feb. 2020.

[23] Katzenschlager Regina, and Andrew J Lees.”Treatment of Parkinson's disease: levodopa as the first choice.”Journal of neurology vol. 249 Suppl 2 (2002): II19-24. 

[24] Müller Thomas.”Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease.”Expert opinion on drug metabolism & toxicology vol. 16, 5 (2020): 403-414. 

[25] Trenkwalder Claudia et al.”Increased dose of carbidopa with levodopa and entacapone improves”off" time in a randomized trial.”Neurology vol. 92, 13 (2019): e1487-e1496. 

[26] Stocchi Fabrizio et al.” An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease.” Expert opinion on pharmacotherapy vol. 22, 8 (2021): 965-972. 

[27] Antonini Angelo et al. ”The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.” Advances in therapy vol. 38, 6 (2021): 2854-2890.  

[28] Amjad Fahd et al. ”Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.” Advances in therapy vol. 36, 9 (2019): 2233-2246. 

[29] Olanow C Warren et al.” Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. ”Journal of Parkinson's disease vol. 11, 1 (2021): 177-186. 

[30] Cacabelos Ramón.”Parkinson's Disease: From Pathogenesis to Pharmacogenomics.” International journal of molecular sciences vol. 18, 3 551. 4 Mar. 2017.

[31] McIntyre Cameron C et al.”Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both.”Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology vol. 115, 6 (2004): 1239-48. 

[32] Southwell Derek G et al.”Before and after the veterans affairs cooperative program 468 study: Deep brain stimulator target selection for treatment of Parkinson's disease.”Parkinsonism & related disorders vol. 48 (2018): 40-44. 

[33] Castrioto Anna, and Elena Moro.”New targets for deep brain stimulation treatment of Parkinson's disease.”Expert review of neurotherapeutics vol. 13, 12 (2013): 1319-28. 

[34] Soulas T et al.”Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease.”Journal of neurology, neurosurgery, and psychiatry vol. 79, 8 (2008): 952-4. 

[35] Krauss Joachim K et al.”Technology of deep brain stimulation: current status and future directions.”Nature reviews. Neurology vol. 17, 2 (2021): 75-87. 

[36] Sonntag Kai-C et al.”Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.”Progress in neurobiology vol. 168 (2018): 1-20. 

[37] Zheng Zhijun, Xiao Wei, Liang Fajun, Zhang Xianbao, Wang Zhen. The effect of acupuncture on the inflammatory response in the brain of Parkinson's disease model rats based on the theory of”gut-brain axis" [J]. Research of Integrated Chinese and Western Medicine, 2020, 12(06):379-382. 

[38] Huang Kai, Bao Chunling, Chen Weiwei, Tu Jinyan, Luo Enli. Effects of electroacupuncture on mitochondrial function in mice with Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine [J]. Acupuncture Research, 2021, 46(01):21-26. 

[39] Cai Weibin, Yang Liu, Yan Xiaanning, Yu Zhuli, Yang Lei, Luo Enli. Effect of head acupoint electroacupuncture on motor function and oxidative stress response in Parkinson's disease mice [J]. Journal of Guangzhou University of Chinese Medicine, 2017, 34(02):204-209.